Shares of Novavax up 11% after positive Phase IIb flu vax results; Scientists turn to DNA nanotechnology for new synthetic vaccines;

 @AlisonBFierce: Sanofi Pasteur successfully combats three of four virus serotypes of dengue in Thailand. Article | Follow @AlisonBFierce

> A new study found that people infected with HIV-2 and then later HIV-1 appear better equipped to fight off the virus. Story

> Scientists have turned to DNA nanotechnology to develop a new class of synthetic vaccines. Article

> A new public-private partnership, the Collaboration for HIV/AIDS Immunological Therapy (CHAIT Initiative), will work to combat HIV/AIDS. Release

> Shares of Novavax ($NVAX) climbed 11% Wednesday after the company released positive results from a Phase IIb clinical trial for its seasonal flu vax. News

> The Indiana State Department of Health unveiled a tool that makes vaccination records available to patients online. Item

> Vaxil BioTherapeutics made its debut on the Tel Aviv Stock Exchange through a merger with Sheldonco. Story (sub. req.)

And Finally... A needle-free flu vaccine will be offered to everyone in the U.K. between the ages of 2 and 17. More

Suggested Articles

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.